Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Adenosine receptor antagonist (1) ·
Adenosine receptor antagonist; dopaminergic (1) ·
Adenosine receptor antagonist; phosphodiesterase inhibitor (1) ·
Alpha-adrenergic agonist; monoamine releaser (1) ·
Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) ·
AMPA modulator; catecholaminergic (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
Dopamine and serotonin reuptake inhibitor; actoprotector (1) ·
Dopamine reuptake inhibitor; tropane analogue (1) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Indirect sympathomimetic; norepinephrine releaser (1) ·
Monoamine releasing agent (8) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Monoamine reuptake inhibitor; sodium channel blocker (1) ·
N-methyl analogue of 2-AI (1) ·
Nicotinic acetylcholine receptor agonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine releaser (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Norepinephrine–dopamine reuptake inhibitor (2) ·
Potent dopamine and norepinephrine reuptake inhibitor (1) ·
Potent dopamine/norepinephrine reuptake inhibitor (1) ·
Selective norepinephrine reuptake inhibitor (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1) ·
'"`UNIQ--vote-00000093-QINU`"' At higher doses β2 selectivity is lost, producing β1 effects (tachycardia, tremor) and hypokalemia from intracellular potassium shift'"`UNIQ--ref-00000094-QINU`"'. (1)
uses:
None (43) ·
'"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"', '"`UNIQ--vote-00000097-QINU`"', '"`UNIQ--vote-00000098-QINU`"' (1) ·
'"`UNIQ--vote-000009BE-QINU`"', '"`UNIQ--vote-000009BF-QINU`"' (1) ·
'"`UNIQ--vote-00000F78-QINU`"', '"`UNIQ--vote-00000F79-QINU`"', '"`UNIQ--vote-00000F7A-QINU`"' (1)
starting dose:
None (43) ·
18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat) (1) ·
MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h (1) ·
Nebulized 500 mcg q6-8h (or with albuterol as DuoNeb); MDI 17 mcg/puff, 2 puffs QID; nasal 0.03% or 0.06% spray BID-TID (1)
preparations:
None (43) ·
18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication) (1) ·
Atrovent HFA 17 mcg/actuation MDI; 500 mcg/2.5 mL nebulizer solution; 0.03% and 0.06% intranasal sprays; with albuterol as DuoNeb / Combivent Respimat (1) ·
MDI 90 mcg/puff; nebulizer solution 0.083% (2.5 mg/3 mL), 0.5%, 0.021%, 0.042%; syrup 2 mg/5 mL; 2 mg, 4 mg tablets; 4 mg, 8 mg ER (1)
fda max:
routes:
onset:
halflife:
bioavailability:
None (43) ·
Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)'"`UNIQ--ref-00000F7C-QINU`"' (1) ·
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"' (1) ·
~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"' (1)
pregnancy:
None (43) ·
Limited data; generally considered acceptable when needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; LABA/LAMA strategies in pregnancy generally favor agents with the most reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Preferred SABA in pregnancy; benefits of asthma control outweigh limited risks.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 46 results in range #1 to #46.